Company Overview and News
KUALA LUMPUR (July 6): Based on corporate announcements and news flow today, stocks that may draw some attention on Monday (July 9) could be MISC, Red Sena, Top Glove, KUB Malaysia, Ta Ann, Protasco and Versatile Creative.
TGLVY 4995 5270 7113 TPGVF 6874 BSMAF 5012 1818
KUALA LUMPUR (July 3): The FBM KLCI looked set to extend its losses today in line with the turbulent regional markets, as it fell 0.43% at the midday break.
HLFBF 5270 UPBMF 8621 7036 1082 4197 5681 BATS 4162 1163 2089 5199 KLKBY 2445 5347 3867 SMEBF TNABY TNABF HIPEF 3719
KUALA LUMPUR: Recent weakness in Red Sena Bhd shares, as the food and beverage (F&B) special purpose acquisition company’s (SPAC) mandated requirement of making a qualifying acquisition (QA) remains elusive, has created a good buying opportunity.
5270 5241 BSMAF 5256 5234 1818
Munchy, which reported a net profit of RM41.34mil on the back of a RM283.67mil revenue in 2015, was earlier said to be the target of locally listed special-purpose acquisition company (SPAC) Red Sena Bhd, which is focused on the food-manufacturing sector. (Picture shows some Munchy products)
Good match: A worker checks products at Munchy’s factory in Batu Pahat. The privately held Munchy Group, which has a global presence with its wafers, biscuits and confectionery products, fit well into the profile of companies that Red Sena targeted.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...